Smoking cessation in chronic obstructive pulmonary disease

  • D.P. T
  • 4


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Chronic obstructive pulmonary disease (COPD) is increasing in prevalence, and is predicted to become the third leading cause of deaths worldwide by 2020. The precise prevalence of COPD is not known, as many individuals with the disease are left undiagnosed, despite the requirement of only simple spirometry testing for disease detection. The major risk factor for the development of COPD is cigarette smoking, with 90% of deaths from COPD directly attributable to smoking. Therefore smoking cessation is the most effective means of halting or slowing the progress of this disease. This review summarizes and compares the differential characteristics of smokers with COPD vs. those without COPD in relation to their smoking behavior and quitting attempts, and discusses the various strategies that can be used to help patients quit and improve their likelihood of long-term smoking cessation. Of the various behavioral interventions available that can increase the likelihood of smoking cessation, one of the simplest and most effective strategies that physicians can use is simply to advise their patients to quit, particularly if this advice is combined with informing the patients of their "lung age". We also discuss the pharmacologic therapies used to enhance the likelihood of quitting, including nicotine replacement, bupropion SR and varenicline, along with novel nicotine vaccines, which are currently undergoing clinical trials. © 2009 Elsevier Ltd. All rights reserved.

Author-supplied keywords

  • *chronic obstructive lung disease/ep [Epidemiology
  • *chronic obstructive lung disease/et [Etiology]
  • *smoking
  • *smoking cessation
  • *tobacco dependence/dt [Drug Therapy]
  • *tobacco dependence/ep [Epidemiology]
  • *tobacco dependence/et [Etiology]
  • *tobacco dependence/th [Therapy]
  • acupuncture
  • amfebutamone/cm [Drug Comparison]
  • amfebutamone/dt [Drug Therapy]
  • anxiety
  • behavior modification
  • clinical trial
  • comorbidity
  • cyto 02 nicqb
  • depression
  • exercise
  • forced expiratory volume
  • human
  • hypnosis
  • morbidity
  • mortality
  • nausea/si [Side Effect]
  • nicotine replacement therapy
  • nicotine vaccine/ct [Clinical Trial]
  • nicotine vaccine/dt [Drug Therapy]
  • nicotine vaccine/im [Intramuscular Drug Administra
  • nicotine/ct [Clinical Trial]
  • nicotine/dt [Drug Therapy]
  • nortriptyline/cm [Drug Comparison]
  • nortriptyline/dt [Drug Therapy]
  • outcome assessment
  • patient counseling
  • patient education
  • placebo
  • practice guideline
  • priority journal
  • review
  • social support
  • spirometry
  • suicidal ideation/si [Side Effect]
  • telephone
  • unclassified drug
  • varenicline/ae [Adverse Drug Reaction]
  • varenicline/cm [Drug Comparison]
  • varenicline/ct [Clinical Trial]
  • varenicline/dt [Drug Therapy]
  • weight gain

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in


  • Tashkin D.P.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free